Shireen Sindi

1. The CAIDE Dementia Risk Score App: The development of an evidence-based mobile application to predict dementia. Shireen Sindi1, Elisabeth Calov2, Jasmine Fokkens2, Tiia Ngandu3, Hilkka Soininen4, Jaakko Tuomilehto3 Miia Kivipelto1,4,5 The Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score allows the prediction of the later risk of dementia based on the risk factor profile present in midlife (age 40 to 65) Background The CAIDE Dementia Risk score is a validated tool to predict dementia risk, based on the presence of vascular risk factors in mid-life. In order to make this prediction tool more widely available to health practitioners and the general public, a mobile application (App) has been developed. Mobile applications are increasingly gaining importance to inform patients, guide them, and facilitate their communication with health care practitioners. In collaboration with Merz Pharmaceuticals, the CAIDE Risk Score App has been developed based on the CAIDE risk factors, which involves high age, low education, mid-life hypertension, hypercholesterolemia, obesity, and physical inactivity, which significantly predict dementia (AUC 0.77; 95% CI 0.71-0.83). With increased risk score, the dementia probability is increased. Methods Results The CAIDE Risk Score App is an evidence-based practical and user-friendly App that complies with security and privacy guidelines. The App is intended for use by patients and health practitioners. It allows patients to detect their risk, provides some suggestions to modify their risk factors and directs them to consulting a health care practitioner if needed. Moreover, it allows practitioners to discuss preventive measures and thereafter monitor whether the patients’ dementia risk has decreased based on interventions and guidance provided. Information Provider: Merz Pharmaceuticals GmbH Category: Medicine Updated: Soon available in the App store Version: 1.0 Size: about 15,8 MB Age rating: 4+ Compatibility: Requires iOS 7; compatible with iPhone, iPad and iPod Touch Data protection Any personal information or patient data saved in the CAIDE Risk application will only be stored locally on the device and cannot be accessed by Merz Pharmaceuticals GmbH. Conclusions The CAIDE Risk Score App is important and unique in detecting the risk to develop dementia through the use of an evidence-based tool. While many Apps have been developed for nutritional guidance, physical activity, pregnancy and diabetes, only a scarce number of Apps have been developed for conditions that are highly prevalent among older adults, such as dementia. The use of the App will encourage people to actively decrease their modifiable risk factors. Future efforts will focus on patients’ and physicians’ evaluations to further improve the App’s efficacy. References: Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk Score for prediction of dementia risk in 20 years among middle aged people: a longitudinal population based study. Lancet Neurology 2006;9:735-41. Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmenr RA. Alzheimers Dement. 2013 Sep 10. pii: S1552-5260. [Epub ahead of print] Shireen Sindi Aging Research Center Karolinska Institutet e-mail: shireen.sindi@ki.se Address: Gävlegatan 16 website: www.ki-su-arc.se SE-113 30 Stockholm Supported by: Fonds de la recherche en santé du Québec (FRSQ) (Canada), Karolinska Institutet (Sweden), Aging Research Center (ARC) (Sweden), the Swedish Research Council for Medical Research (Vetenskapsrådet), Swedish Brain Power (Sweden), Academy of Finland (Finland), Merz Pharmaceuticals GmbH (Germany), University of Eastern Finland, University of Stockholm (Sweden). 1. Aging Research Center (ARC), Karolinska Institutet, Stockholm, Sweden 2. Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany 3. Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland 4. Department of Neurology, University of Eastern Finland, Kuopio, Finland 5. Karolinska Institutet Alzheimer Disease Research Center, Stockholm, Sweden Presented at the 13°International Geneva/Springfield Symposium , 26.-29. March 2014